• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

pertuzumab

Halozyme: Elegant Transformation of Drugs From Intravenous to Subcutaneous
Posted inPharma & Biotech

Halozyme: Elegant Transformation of Drugs From Intravenous to Subcutaneous

April 14, 2021September 8, 2022

Easy and quick administration of biological drugs. All for the convenience of patient care.

Enhertu: Most Powerful Drug to Treat Advanced HER2-Positive Breast Cancer
Posted inNew Drugs, Oncology, Regulatory

Enhertu: Most Powerful Drug to Treat Advanced HER2-Positive Breast Cancer

March 31, 2021September 8, 2022

Trastuzumab deruxtecan, developed by AstraZeneca and Daiichi Sankyo, will save lives when Herceptin, Perjeta, and Kadcyla haven’t worked.

BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News